Vascular Anomalies Center
Featured Clinical Trials
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
This Phase 2 study evaluates the safety and effectiveness of the RLY-2608 medication in children and adults with PIK3CA-related overgrowth conditions.
A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (SELVA)
This Phase 3 study evaluates the QTORIN 3.9% rapamycin gel topical treatment in individuals aged 3 years and older with microcystic lymphatic malformations.
Alpelisib in Pediatric and Adult Patients with Lymphatic Malformations Associated with a PIK3CA Mutation (EPIK-L1)
This Phase 2/3 study evaluates the safety and effectiveness of the targeted medicine Alpelisib in children and adults with lymphatic malformations caused by PIK3CA mutations.
A Study of the Safety and Tolerability in Participants with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated with Miransertib (MK-7075) in Other Studies (MK-7075-006)
This Phase 2 study evaluates the targeted medicine miransertib in children and adults with PROS or Proteus Syndrome.
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)
This Phase 2 study evaluates the targeted medicine Alpelisib in children and adults with symptomatic or progressive PIK3CA-Related Overgrowth Spectrum (PROS).
For a complete list of clinical trials offered at Texas Children's Hospital, visit clinicaltrials.gov
Explore more
Health Briefs
Apr 13, 2023
Mom Helped Save Son's Life When He Told Her to Call 911 for Headache: 'Listen to Your Kids'
Read more
News Release
Oct 18, 2023
The Vascular Anomalies Center at Texas Children's Named Among Best in The Nation by Cure HHT
